← Back
Data updated: Jun 28, 2026
SICOR BIOTECH
Biotech Pharmaceuticals
SICOR BIOTECH is a biotechnology company with 1 FDA-approved products.
2012
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Biologics
SICOR BIOTECH's Key Drugs
SICOR BIOTECH's core commercial portfolio centers on GRANIX — its most strategically important drugs approved in the last 15 years.
SICOR BIOTECH's Recent FDA Approvals
New NDA/BLA approvals for SICOR BIOTECH over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
SICOR BIOTECH's Therapeutic Areas
Disease areas where SICOR BIOTECH has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
SICOR BIOTECH Pipeline Snapshot
Active clinical trials for SICOR BIOTECH across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • GRANIX leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2012-08-29
- Latest
- 2023-11-21
- Applications
- 1